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preparative regimen consisting of busulfan, cyclophosphamide,
and anti-thymocyte globulin for a 5 out of 6 HLA-antigen-
matched unrelated donor cord blood transplant. Graft-versus-
host disease (GVHD) prophylaxis consisted of cyclosporine and
methylprednisolone, and the patient experienced isolated acute
skin GVHD. Notably, several astrocytoma lesions regressed or
decreased in size between 3 and 8 months after transplantation,
associated with a lymphocytic CSF pleiocytosis with elevated
CSF protein. The patient remains leukemia-free with stable
brain lesions 25 months after transplantation. This case illus-
trates the potential for donor-derived immune cells to control
brain tumors, and suggests that allogeneic bone marrow trans-
plantation may represent an important immunotherapeutic
strategy for the aggressive treatment of poor-prognosis brain
tumors. Future clinical protocols should seek to further charac-
terize the nature of the immune response to brain tumors after
allogeneic bone marrow transplantation.
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USE OF CHROMATIN MODIFYING AGENTS FOR EX VIVO EXPANSION OF
HUMAN UMBILICAL CORD BLOOD STEM CELLS
Hoffman, R.1, Hiroto, A.1, Mahmud, N.1 University of Illinois at
Chicago, Chicago, IL.
The ﬁxed number of hematopoietic stem cells (HSCs) within a
single cord blood (CB) unit has limited the use of CB for allogeneic
transplantation in adults. Efforts to promote self-renewal and ex-
pansion of HSCs have been met with limited success. Using pres-
ently available ex vivo culture techniques, HSCs lose their func-
tional properties in proportion to the number of cellular divisions
they have undergone. We hypothesized that chromatin modifying
agents, 5-aza-2-deoxycytidine (5azaD) and histone deacetylase
inhibitor, trichostatin A (TSA) could reactivate pivotal genes re-
quired for retaining the functional properties of dividing HSC to
permit transplantation of adults. A 12.5-fold expansion was ob-
served in the 5azaD/TSA treated CD34CD90 cell cultures
containing SCF, thrombopoietin, and FLT3 ligand (cytokines) in
comparison to the input cell number. Despite 9 days of culture,
35.4%  5.8% (n  10) of the total cells in the cultures exposed to
chromatin modifying agents were CD34 CD90 compared to
1.40%  0.32% in the culture containing cytokines alone. The
CD34CD90 cells were associated with a 9.8-fold increase in
the numbers of CFU-mix and 11.5-fold expansion of cobblestone
area-forming cells (CAFC). The frequency of SCID repopulating
cells (SRC) was 1 in 26,537 in primary CB CD34CD90 cells
but was increased to 1 in 2745 CD34CD90 cells following 9
days of culture in the presence of 5azaD/TSA resulting in a 9.6-
fold expansion of the number of SRC. In contrast, the cultures
lacking 5azaD/TSA had a net loss of both CFC/CAFC as well as
SRC. The expansion of cells maintaining CD34CD90 pheno-
type was not due to the retention of a quiescent population of cells
since all of the CD34CD90 cells in the culture had undergone
cellular division. CD34CD90 cells that had undergone 5–10
cellular divisions in the presence of 5azaD/TSA but not in the
absence still retained the ability to repopulate NOD/SCID mice.
We next assessed the effect of 5azaD/TSA treatment on the ex-
pression of HOX-B4, a transcription factor which has been impli-
cated in HSC self-renewal. A signiﬁcantly higher level of HOXB4
protein was detected by western blot analysis after 9 days of culture
in the cells treated with 5azaD/TSA as compared to cells exposed
to cytokines alone. The almost 10-fold increase in SRC achieved
using the chromatin modifying agents may be sufﬁcient to increase
the numbers of engraftable HSC within a single human CB unit for
adult recipients.
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ADULT HUMAN HEMATOPOIETIC CELLS DIFFERENTIATE INTO MATURE
T CELLS VIA A CD3-48- INTERMEDIATE WITHIN THE MOUSE THYMIC
MICROENVIRONMENT; A NEW MODEL SYSTEM FOR THE STUDY OF
HUMAN THYMOCYTE DEVELOPMENT FURTHER ENHANCED BY ANTI-
MURINE c-Kit mAB
Kraft, D.L.1, Czechowicz, A.1, Weissman, I.I.1 Stanford University
Depts of Pediatric Hematology/Oncology and Pathology, Stanford, CA.
Normal T cell differentiation occurs within the thymus. We
previously found that human thymocyte precursors develop via
a novel CD3-48- intermediate population, utilizing SCID-hu
thymic grafts (Kraft,Weissman,Waller;JEM). We have recently
worked to develop a more convenient robust model of human
hematopoiesis utilizing RAG2/Common Gamma Chain double
KO mice transplanted with hematopoietic progenitor cells from
adult human donors, and hypothesized that human engraftment
would be enhanced by selective inhibition of murine hemato-
poisis by administration of anti-murine c-Kit mAb. Methods:
Mobilized CD34 cells from healthy adults were obtained to
	90% purity by CliniMacs. 2–8  105 CD34 cells were
injected intrahepatically into newborn RAG2 DKO pups fol-
lowing 4Gy of irradiation. At serial time points, human CD45
chimerism was measured within the recipient marrow, blood,
spleen, liver, lymph node, and thymus. A subset of recipients
were treated with the anti-murine c-Kit mAb (ACK2) starting at
D 14. Results: Human engraftment was detectable in CD34
transplanted mice, and this was enhanced by suppression of
murine hematopoiesis by anti c-Kit mAb. Robust human thy-
mopoeisis was observed. A mean of 63% of cells within the
thymus were human derived. At earlier time points (4–6 weeks
post transplant) the recipient thymus were found to contain high
fractions of CD45CD348 cells (making up 30–40% of
human cells within the thymus) and the CD348 (20–30%)
and CD48 (30–70%) intermediate populations with very
rare mature CD348 or CD348 T cells. At later time
points the fraction of immature CD348 and CD348
populations declined and increasing populations of mature
CD348 and CD34-8 populations were identiﬁed in
distributions similar to a normal thymus. Conclusions: Human
T cell development appears to progress normally within a mu-
rine thymic microenvironment. The early development of a
CD348 intermediate suggests that T cell development
occurs via this population, unlike the CD348 intermediate
found in mice thymopoesis, suggesting that the pathway of
human T cell differentiation is intrinisic to the human thymo-
cytes, and is independent of whether the thymic stroma is
human or murine. This robust model system enabling study of
human thymopoesis utilizing hematopoietic stem cells from
normal and diseased adults human donors may provide signiﬁ-
cant advantages for the study of human intrathymic T cell
differentiation and function in vivo.
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CD8/TCR GRAFT FACILITATING CELLS ENHANCE HSC FUNCTION VIA
INDUCTION OF LOW LEVELS OF TNF-	
Ildstad, S.T.1, Rezzoug, F.1, Huang, Y.1, Wysoczynski, M.2,
Schanie, C.L.1, Ratajczak, M.Z.2, Fugier-Vivier, I.J.1 1. Institute for
Cellular Therapeutics, University of Louisville, Louisville, KY; 2. Stem
Cell Biology Program at James Brown Cancer Center, University of
Louisville, Louisville, KY.
Approaches to enhance engraftment of HSC when cell num-
bers are limiting remain an elusive goal in bone marrow trans-
plantation. We recently reported that CD8/TCR facilitating
cells (FC), a subpopulation of BM cells containing predomi-
nantly B220/CD11c/CD11b tolerogenic precursor-plasma-
cytoid dendritic cells, enhance HSC engraftment in allogeneic
recipients. FC are themselves tolerogenic, directly preventing
GVHD. Additionally, FC signiﬁcantly enhance engraftment of
limiting numbers of HSC in syngeneic recipients. In the present
studies, we investigated the mechanism of FC function. Here we
show for the ﬁrst time that FC signiﬁcantly increase HSC
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clonogenicity in vitro via production of inducible TNF-
 upon
contact with HSC. Co-culture of FC with HSC induces pro-
duction of physiologically relevant low levels of TNF-
 by FC.
FC from TNF-
-deleted (TNF-
/) mice are signiﬁcantly
impaired in function in vitro and in facilitating HSC engraft-
ment in vivo in syngeneic recipients as well as allogeneic recip-
ients. A syngeneic model for limiting numbers of HSC (c-Kit/
Sca-1/Lin) was used to evaluate facilitation by TNF-
/
FC. Notably, while 80% of recipients of 500 B6 HSC  30,000
B6 FC engraft durably, none of the recipients of 500 B6 HSC
plus 30,000 TNF-
/ FC engrafted. Furthermore, neutraliza-
tion of TNF-
 on FC using anti-TNF antibody results in loss of
FC effect on HSC clonogenicity in vitro, conﬁrming a direct
and critical role for TNF-
 in FC function. Notably, co-culture
of FC with HSC is associated with signiﬁcant upregulation of
the anti-apoptotic I-B family member Bcl-3 in HSC. Blocking
of TNF-
 on FC abrogates the upregulation of Bcl-3 in HSC.
Taken together, these ﬁndings demonstrate that TNF-
-in-
duced in FC by contact with HSC affects highly primitive HSC
and identify Bcl-3 as a possible pathway for TNF-
 in promot-
ing HSC survival and engraftment efﬁciency.
380
SUPERIOR EX VIVO CORD BLOOD TNC AND HEMATOPOIETIC PROGEN-
ITOR CELL EXPANSION FOLLOWING CO-CULTURE WITH BONE MAR-
ROW-DERIVED MESENCHYMAL STEM CELLS
Robinson, S.N.1, Ng, J.1, Niu, T.1, Yang, H.1, McMannis, J.D.1,
Karandish, S.1, Kaur, I.1, Fu, P.1, Del Angel, M.1, Messinger, R.1,
Flagge, F.1, de Lima, M.1, Decker, W.1, Xing, D.1, Champlin, R.1,
Shpall, E.J.1 Department of Blood and Marrow Transplantation, Uni-
versity of Texas M. D. Anderson Cancer Center, Houston, TX.
One factor limiting the therapeutic efﬁcacy of cord blood (CB)
hematopoietic progenitor cell (HPC) transplantation is the low
cell dose of the graft. Low cell dose is associated with an
increased incidence of delayed or failed engraftment. However,
cell dose can be increased and the efﬁcacy of CB transplantation
potentially improved by ex vivo CB expansion prior to trans-
plantation. Two ex vivo CB expansion techniques were com-
pared and hematopoietic output followed by measuring total
nucleated cell (TNC), CD133 and CD34, colony-forming
unit (CFU) and cobblestone area-forming cell (CAFC) num-
bers. Technique 1: Ex vivo culture of CD133-selected cells;
and Technique 2: Co-culture of unmanipulated CB with allo-
geneic bone-marrow-derived mesenchymal stem cell (MSC)
monolayers. In both cases, ex vivo culture was performed in
medium supplemented with granulocyte colony-stimulating fac-
tor (G-CSF), stem cell factor (SCF) and either thrombopoietin
(TPO) or megakaryocyte growth and differentiation factor
(MDGF). When compared to ex vivo liquid culture, ex vivo
CB-MSC co-culture (1) required less cell manipulation result-
ing in less initial HPC loss and (2) markedly improved TNC
(	10-fold), CFU (	25-fold), CD133 (	7-fold) CD34 (	14-
fold), CAFCwk2 (	200-fold), and CAFCwk6 (	44-fold) output.
In addition, MSC have also been shown to promote hematopoi-
etic engraftment in animal models and to possess immunomodu-
latory activities and have been shown to reduce the severity of
graft versus host disease. One concern associated with any ex
vivo expansion strategy is that short-term reconstituting, lower
quality HPC will be expanded at the expense of long-term
reconstituting, higher quality HPC, thereby signiﬁcantly im-
pacting the hematopoietic reserve of the graft. Here we dem-
onstrate that although neither technique signiﬁcantly expanded
the more primitive CAFCwk6 population, they were better pre-
served in the CB-MSC co-culture system. Although the expan-
sion of the more mature components of the hematopoietic
system (TNC, CFU, CD133, CD34, and CAFCwk2) in both
cases was at the expense of the more primitive HPC, in neither
case was the CAFCwk6 compartment completely exhausted,
thereby potentially preserving part of the hematopoietic reserve
of the graft. In improving TNC and HPC expansion, ex vivo
CB-MSC co-culture therefore holds promise for improving
engraftment kinetics and post-transplant complications in CB
transplant recipients.
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IDIOPATHIC SECONDARY POST-TRANSPLANT THROMBOCYTOPENIA
(ISPT) FOLLOWING AUTOLOGOUS HEMATOPOIETIC PROGENITOR
CELL TRANSPLANTATION (HPCT) IS ASSOCIATED WITH TRANSPLAN-
TATION OF LOWER NUMBERS OF PRIMITIVE HEMATOPOIETIC PRO-
GENITORS
Ninan, M.J.1, Arellano, M.2, Philip, A.3, Langston, A.2, Flowers, C.R.2,
Lonial, S.2, Kaufman, J.2, Lechowicz, M.2, Khoury, J.H.2, Roback, J.2,
Waller, E.K.2 1. Atlanta Medical Center, Atlanta, GA; 2. Winshp
Cancer Institute Emory University, Atlanta, GA; 3. Emory University
Stem Cell Laboratory, Atlanta, GA.
Background: Platelet counts often drop after initial hemato-
poietic engraftment. We hypothesized that secondary thrombo-
cytopenia is related to the stem cell content of the graft. Meth-
ods: We performed a retrospective analysis of 323 consecutive
patients who underwent autologous blood (97%) or BM (3%)
HPCT between 2000 and 2005 for Hodgkin’s lymphoma (n 
53), NHL (n  85), multiple myeloma (n  166), acute leuke-
mia (n  16), and solid tumor (n  5). ISPT was deﬁned as a
	50% decline in blood platelets following initial engraftment to
a value less than 100 K/mcL, in the absence of infection or
relapse, in the ﬁrst 100 days post-transplant. Engraftment,
transfusions, infections, relapse, and survival were recorded with
a median follow-up of 410 days. Results: 303 patients were
evaluable and achieved a transfusion-independent platelet count
of 	20K/mcL, at a median of 17 days post-transplant. The
maximal platelet count was a median of 192 K/mcL and oc-
curred on a median of 22 days. Sixty-three patients (21%) had
secondary thrombocytopenia after initial engraftment, with 3
cases of relapse and 11 cases of sepsis, leaving 49 patients (15%)
with ISPT, and 254 controls. Patients with ISPT engrafted at a
median of 17 days, with a maximal platelet count of 162 K/mcL
on day 19. Platelet counts in ISPT patients dropped to a nadir
of 34 K/mCL (range 4 K–98 K/mcL) on day 35 with subsequent
recovery to a median of 148 K/mcL on day 71. Mean CD34
cells/kg transplanted in ISPT patients (9  7  10E6/kg) were
similar to cell doses transplanted in controls (11  14  10E6/
kg), but IPST patients received fewer CD34CD38 HPC
(0.08  0.08  10E6/kg) versus controls (0.13  0.24  10E6/
kg, P  .005, 2 sided T-test). HIT and anti-platelet antibodies
were absent, and only 16% of BM biopsies in patients with ISPT
had increased megakaryocytes. Fourteen of forty-nine patients
with ISPT received steroids and/or IVIG and had similar plate-
let recoveries to those not treated. Lymphoma patients and
recipients of busulfan conditioning regimens were over-repre-
sented in patients with ISPT compared to controls (P  .001).
Three-year actuarial survival was not signiﬁcantly different be-
tween the 49 ISPT cases (79%) versus the 254 controls (76%).
Conclusions: ISPT occurring within the ﬁrst 100 days after
autologous HPCT is common, and associated with transplanta-
tion of lower numbers of phenotypically primitive HPC. IPST
does not appear to be an auto-immune phenomenon, is self-
limited, and is not associated with adverse long-term survival
(Table1).
Table 1. Comparison of IPST Cases vs Controls
Age
(years)
Gender
(male)
HL and
NHL*
Pre-trx
XRT
Median
day Plt
engrafted
BM
cellularity
day 40–45
Platelet
transfusion
increment
IPST
N  49 48 years 55% 73% 4% 17 days 35% 32K/mcL
Controls
N 
254 51 years 63% 36% 7% 17.5 days 34% 31K/mcL
*P  .001
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